Depside trimeric compounds for skeletal muscle modulation
AssigneeSociete des Produits Nestle S.A.
InventorsDenis Marcel Barron, Benjamin Brinon, Jerome Feige, Sonia Karaz, Joris Michaud, Yann Ratinaud, Pascal Stuelsatz
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel depside trimeric compounds for improving skeletal muscle plasticity regeneration to maintain or increase muscle function and/or muscle mass by modulating muscle stem cells. For example, the present invention is useful for subjects to promote muscle repair and/or subjects suffering from precachexia, cachexia, sarcopenia, myopathy, dystrophy and/or recovery after muscle injury or surgery.
Claims18
A method to maintain or increase skeletal muscle function and/or mass in a subject, and/or substantially prevent or reduce muscle wasting in a subject comprising administering to a subject a compound represented by formula (I):
- wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13, are each independently selected from the group consisting of H;
- OH;
- OMe;
- O-acyl;
- O-glycoside;
- C-glycoside;
- acylated O-glycoside;
- acylated C-glycoside;
- sulfated O-glycoside;
- sulfated C-glycoside;
- a halogen;
- a primary, secondary, or tertiary alcohol;
- a ketone;
- an aldehyde;
- a carboxylic acid;
- an ester;
- a primary, secondary, or tertiary amine;
- a primary or secondary amide;
- a cyano;
- a nitro;
- a sulfonate;
- a sulfate;
- a substituted and/or branched C1 to C19 alkyl;
- a substituted and/or branched, C2 to C19 alkenyl;
- a substituted and/or branched, C4 to C19 polyalkenyl;
- a substituted and/or branched C2 to C19 alkynyl, or a substituted and/or branched C4 to C19 polyalkynyl;
- a substituted and/or branched, C4 to C19 polyunsaturated chain;
- and R14 is selected from the group consisting of H;
- Me;
- a sugar;
- or a sugar alcohol.
9-10. (canceled)
12-13. (canceled)
15-16. (canceled)
A method of treatment for cachexia or precachexia comprising administering to a human or animal subject an effective amount of a compound to maintain or increase skeletal muscle function and/or mass in a subject, and/or substantially prevent or reduce muscle wasting in a subject comprising administering to a subject a compound represented by formula (I):
- wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13, are each independently selected from the group consisting of H;
- OH;
- OMe;
- O-acyl;
- O-glycoside;
- C-glycoside;
- acylated O-glycoside;
- acylated C-glycoside;
- sulfated O-glycoside;
- sulfated C-glycoside;
- a halogen;
- a primary, secondary, or tertiary alcohol;
- a ketone;
- an aldehyde;
- a carboxylic acid;
- an ester;
- a primary, secondary, or tertiary amine;
- a primary or secondary amide;
- a cyano;
- a nitro;
- a sulfonate;
- a sulfate;
- a substituted and/or branched C1 to C19 alkyl;
- a substituted and/or branched, C2 to C19 alkenyl;
- a substituted and/or branched, C4 to C19 polyalkenyl;
- a substituted and/or branched C2 to C19 alkynyl, or a substituted and/or branched C4 to C19 polyalkynyl;
- a substituted and/or branched, C4 to C19 polyunsaturated chain;
- and R14 is selected from the group consisting of H;
- Me;
- a sugar;
- or a sugar alcohol.
21-26. (canceled)
Dependencies are inferred from the claim text.